Inavolisib

Curated

← predicts response to

PIK3CA E453GSNV

sensitivity

Curated

← predicts response to

PIK3CA E453DSNV

sensitivity

Curated

← predicts response to

PIK3CA E453ASNV

sensitivity

Curated

← predicts response to

PIK3CA E453QSNV

sensitivity

Curated

← predicts response to

PIK3CA E453KSNV

sensitivity

Curated

← predicts response to

PIK3CA M1043TSNV

sensitivity

Curated

← predicts response to

PIK3CA M1043ISNV

sensitivity

Curated

← predicts response to

PIK3CA M1043VSNV

sensitivity

Curated

← predicts response to

PIK3CA C420RSNV

sensitivity

Curated

← predicts response to

PIK3CA R88QSNV

sensitivity

Curated

← predicts response to

PIK3CA N345YSNV

sensitivity

Curated

← predicts response to

PIK3CA N345TSNV

sensitivity

Curated

← predicts response to

PIK3CA N345SSNV

sensitivity

Curated

← predicts response to

PIK3CA N345ISNV

sensitivity

Curated

← predicts response to

PIK3CA N345HSNV

sensitivity

Curated

← predicts response to

PIK3CA N345DSNV

sensitivity

Curated

← predicts response to

PIK3CA N345KSNV

sensitivity

Curated

← predicts response to

PIK3CA G1049DSNV

sensitivity

Curated

← predicts response to

PIK3CA G1049CSNV

sensitivity

Curated

← predicts response to

PIK3CA G118DSNV

sensitivity

Curated

← predicts response to

PIK3CA G106DSNV

sensitivity

Curated

← predicts response to

PIK3CA G106ASNV

sensitivity

Curated

← predicts response to

PIK3CA G106SSNV

sensitivity

Curated

← predicts response to

PIK3CA G1049ASNV

sensitivity

Curated

← predicts response to

PIK3CA G106RSNV

sensitivity

Curated

← predicts response to

PIK3CA G106VSNV

sensitivity

Curated

← predicts response to

PIK3CA G1049RSNV

sensitivity

Curated

← predicts response to

PIK3CA G1049SSNV

sensitivity

Curated

← predicts response to

PIK3CA Q546HSNV

sensitivity

Curated

← predicts response to

PIK3CA K111RSNV

sensitivity

Curated

← predicts response to

PIK3CA K111NSNV

sensitivity

Curated

← predicts response to

PIK3CA K111ESNV

sensitivity

Curated

← predicts response to

PIK3CA Q546LSNV

sensitivity

Curated

← predicts response to

PIK3CA Q546RSNV

sensitivity

Curated

← predicts response to

PIK3CA Q546PSNV

sensitivity

Curated

← predicts response to

PIK3CA Q546ESNV

sensitivity

Curated

← predicts response to

PIK3CA Q546KSNV

sensitivity

Curated

← predicts response to

PIK3CA E542VSNV

sensitivity

Curated

← predicts response to

PIK3CA E542RSNV

sensitivity

Curated

← predicts response to

PIK3CA E542GSNV

sensitivity

Curated

← predicts response to

PIK3CA E542DSNV

sensitivity

Curated

← predicts response to

PIK3CA E542ASNV

sensitivity

Curated

← predicts response to

PIK3CA E542QSNV

sensitivity

Curated

← predicts response to

PIK3CA E542KSNV

sensitivity

Curated

← predicts response to

PIK3CA E545RSNV

sensitivity

Curated

← predicts response to

PIK3CA E545LSNV

sensitivity

Curated

← predicts response to

PIK3CA E545DSNV

sensitivity

Curated

← predicts response to

PIK3CA E545VSNV

sensitivity

Curated

← predicts response to

PIK3CA E545GSNV

sensitivity

Curated

← predicts response to

PIK3CA E545ASNV

sensitivity

Curated

← predicts response to

PIK3CA E545QSNV

sensitivity

Curated

← predicts response to

PIK3CA E545KSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047TSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047QSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047PSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047NSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047ISNV

sensitivity

Curated

← predicts response to

PIK3CA H1047DSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047LSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047YSNV

sensitivity

Curated

← predicts response to

PIK3CA H1047RSNV

sensitivity

Curated

Inavolisib targets …TARGETS1 of 1
→ targets	PIK3CA	—	INHIBITOR	—	1	Curated	chembl	graph →

Inavolisib targets …TARGETS1 of 1

→ targets

PIK3CA

—

INHIBITOR

—

Curated

Inavolisib investigated for …INVESTIGATED_FOR4 of 4
→ investigated for	Malignant Breast Neoplasmcancer_family 8 source records aggregated	supports	A	Malignant Breast Neoplasm	8	Curated	civic	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	2	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Endometrial Neoplasmsubtype	unknown	1	Endometrial Neoplasm	1	Curated	chembl	graph →

Inavolisib investigated for …INVESTIGATED_FOR4 of 4

→ investigated for

Malignant Breast Neoplasmcancer_family

8 source records aggregated

supports

Curated

→ investigated for

Breast Neoplasmcancer_family

unknown

Breast Neoplasm

Curated

→ investigated for

Neoplasmcancer_family

unknown

Neoplasm

Curated

→ investigated for

Endometrial Neoplasmsubtype

unknown

Endometrial Neoplasm

Curated

Inavolisib investigated in trials for …INVESTIGATED_IN_TRIALSderived11 of 11
→ investigated in trials for	Malignant Breast Neoplasmcancer_family 13 trials (12 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colorectal Neoplasm 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 3 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Endometrial Neoplasm 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Endometrial Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Castration-Resistant Prostate Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Castration-Resistant Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Early Stage Breast Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Early Stage Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	HER2-Positive Breast Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Ovarian Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Triple-Negative Breast Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →

Inavolisib investigated in trials for …INVESTIGATED_IN_TRIALSderived11 of 11

→ investigated in trials for

Malignant Breast Neoplasmcancer_family

13 trials (12 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

Malignant Colorectal Neoplasm

→ investigated in trials for

3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Colorectal Neoplasm

Observed

→ investigated in trials for

Solid Neoplasm

3 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Solid Neoplasm

Observed

Malignant Endometrial Neoplasm

→ investigated in trials for

2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Endometrial Neoplasm

Observed

Castration-Resistant Prostate Carcinoma

→ investigated in trials for

1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Castration-Resistant Prostate Carcinoma

Observed

Early Stage Breast Carcinoma

→ investigated in trials for

1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Early Stage Breast Carcinoma

Observed

HER2-Positive Breast Carcinoma

→ investigated in trials for

1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

HER2-Positive Breast Carcinoma

Observed

Lung Non-Small Cell Carcinoma

→ investigated in trials for

1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Lung Non-Small Cell Carcinoma

Observed

→ investigated in trials for

Malignant Neoplasm

1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Neoplasm

Observed

Malignant Ovarian Neoplasm

→ investigated in trials for

1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Ovarian Neoplasm

Observed

Triple-Negative Breast Carcinoma

→ investigated in trials for

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Triple-Negative Breast Carcinoma

Observed

Inavolisib studied in …STUDIED_INderived10 of 28show all (up to 200)
→ studied in	NCT05646862Phase 3 · recruiting A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy · 28 trials list this drug (24 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07054190Phase 2 · recruiting A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer · 28 trials list this drug (24 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05708235Phase 2 · active not recruiting A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population · 28 trials list this drug (24 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05894239Phase 3 · recruiting A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer · 28 trials list this drug (24 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07748208Phase 2 · not yet recruiting A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes · 28 trials list this drug (24 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04191499Phase 2/Phase 3 · active not recruiting A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer · 28 trials list this drug (24 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04929223Phase 1 · recruiting A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) · 28 trials list this drug (24 active)	—	—	Malignant Colorectal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05306041Phase 2 · recruiting Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer · 28 trials list this drug (24 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03424005Phase 1/Phase 2 · recruiting A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer · 28 trials list this drug (24 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04931342Phase 2 · active not recruiting A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors · 28 trials list this drug (24 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →

Inavolisib studied in …STUDIED_INderived10 of 28show all (up to 200)

→ studied in

NCT05646862Phase 3 · recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy · 28 trials list this drug (24 active)

—

Observed

→ studied in

NCT07054190Phase 2 · recruiting

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer · 28 trials list this drug (24 active)

—

Observed

→ studied in

NCT05708235Phase 2 · active not recruiting

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population · 28 trials list this drug (24 active)

—

Observed

→ studied in

NCT05894239Phase 3 · recruiting

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer · 28 trials list this drug (24 active)

—

Observed

→ studied in

NCT07748208Phase 2 · not yet recruiting

A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes · 28 trials list this drug (24 active)

—

Observed

→ studied in

NCT04191499Phase 2/Phase 3 · active not recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer · 28 trials list this drug (24 active)

—

Observed

Malignant Colorectal Neoplasm

→ studied in

NCT04929223Phase 1 · recruiting

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) · 28 trials list this drug (24 active)

—

Observed

HER2-Positive Breast Carcinoma

→ studied in

NCT05306041Phase 2 · recruiting

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer · 28 trials list this drug (24 active)

—

Observed

→ studied in

NCT03424005Phase 1/Phase 2 · recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer · 28 trials list this drug (24 active)

—

Observed

Malignant Ovarian Neoplasm

→ studied in

NCT04931342Phase 2 · active not recruiting

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors · 28 trials list this drug (24 active)

—

Observed